Scorpius

Scorpius Holdings is an integrated biotechnology company that has transitioned from a drug development focus into a specialized Contract Development and Manufacturing Organization (CDMO). Operating primarily through its subsidiary, Scorpius BioManufacturing, the company provides end-to-end services for biologics, including process development, analytical testing, and cGMP manufacturing for mammalian and microbial modalities. Its state-of-the-art facility in San Antonio, Texas, is designed to support complex large-molecule programs from pre-clinical stages through clinical trials. While pivoting toward manufacturing services, the company maintains a legacy pipeline of immunotherapy candidates and a commercial-stage asset for the treatment of anthrax. Scorpius aims to address the industry-wide shortage of clinical-scale manufacturing capacity for advanced therapeutic modalities.